Paper Details

  1. Home
  2. Paper Details

Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.

Author: BurkeJoshua, CarrBruce, ChwaliszKristof, DmowskiW Paul, GarnerElizabeth, JiangPing, JimenezRoland, O'BrienChris

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Elagolix, a medication for endometriosis-associated pain, had minimal impact on bone mineral density (BMD) and demonstrated similar efficacy to DMPA-SC. The most common side effects were headache, nausea, and nasopharyngitis. This suggests that elagolix is a potentially effective and safe option for managing endometriosis-associated pain.
Paper Details　
Original Abstract of the Article :
This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD), in women with endometriosis-associated ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212335/

データ提供：米国国立医学図書館（NLM）

Elagolix vs. DMPA-SC: A Bone-Friendly Choice for Endometriosis?

Endometriosis, a condition where uterine lining-like tissue grows outside the uterus, can cause significant pain and affect fertility. This study compared the effects of elagolix, an oral GnRH antagonist, and subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD) in women with endometriosis-associated pain. The study also evaluated the effectiveness of both treatments in reducing endometriosis-associated pain.

Preserving Bone Health While Managing Endometriosis

The study found that both elagolix and DMPA-SC induced minimal changes in BMD over a 24-week treatment period, suggesting that both therapies have minimal impact on bone health. Elagolix was found to be statistically noninferior to DMPA-SC in reducing dysmenorrhea and nonmenstrual pelvic pain, indicating that it is an effective treatment for endometriosis-associated pain.

Navigating the Treatment Options for Endometriosis

As a gynecologist, I'm always searching for treatments that effectively manage endometriosis while minimizing potential side effects, particularly those affecting bone health. This study provides valuable insights into the comparative effects of elagolix and DMPA-SC, suggesting that elagolix may be a good option for women with endometriosis-associated pain who are concerned about bone health. This research is like a cool spring in the desert of endometriosis management, offering a new and potentially bone-friendly treatment option. It's a reminder that the field of reproductive health is continuously evolving, with new and innovative therapies emerging to improve patient care.

Dr.Camel's Conclusion

This study provides valuable information for clinicians and patients seeking effective and bone-friendly treatments for endometriosis. It highlights the potential of elagolix as an alternative to DMPA-SC, offering comparable pain relief with minimal impact on bone health. It's a reminder that the journey towards effective endometriosis management is a continuous search for safer and more effective therapies.

Date :
  1. Date Completed 2015-06-24
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

25249568

DOI: Digital Object Identifier

PMC4212335

Related Literature

Article Analysis
・Effects of elagolix
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.